Perrigo Expands OTC Growth Strategy With Rx-To-OTC Switch Licensing For Nasonex®
- Wednesday, August 8, 2018, 23:11
- Finance
- Add a comment
DUBLIN, Aug. 9, 2018 /PRNewswire/ — Perrigo Company plc (NYSE; TASE: PRGO) announced today that it has entered into a licensing agreement with a subsidiary of Merck & Co, Inc., Kenilworth, NJ, USA for the exclusive rights in the United States to pursue regulatory approval for a…
Source: https://www.prnewswire.com:443/news-releases/perrigo-expands-otc-growth-strategy-with-rx-to-otc-switch-licensing-for-nasonex-300694573.html
About the Author
adminasapcorp has written 41528 stories on this site.